DelistingAug 5, 2026, 04:38 PM
Genprex Regains Nasdaq Bid Price Compliance
AI Summary
Genprex, Inc. announced it has formally regained compliance with Nasdaq's $1.00 Minimum Bid Price requirement, as notified by the Nasdaq Hearings Panel on August 4, 2026. This follows a previous exception granted on July 29, 2026, allowing the company to continue its listing. The Panel will maintain jurisdiction until December 7, 2026, during which Genprex must maintain a closing bid price at or above $1.00 for each trading day. The company also faces a seven-day window to address any other listing rule deficiencies that may arise before December 7, 2026, or risk delisting.
Key Highlights
- Genprex regained compliance with Nasdaq's $1.00 minimum bid price rule.
- Formal notification received from Nasdaq Panel on August 4, 2026.
- Nasdaq Panel previously granted an exception on July 29, 2026.
- Company must maintain $1.00 closing bid price until December 7, 2026.
- Nasdaq Panel retains jurisdiction over Genprex until December 7, 2026.
- Seven calendar days to cure any other listing rule deficiencies.
Price Impact
More from GNPX